Published 2019-01-09
Hasroni Fathurrahman Doddy M Soebadi Lukman Hakim


Objective: To analyze, measure, compare, prove, and evaluate effectiveness of silodosin, diclofenac sodium, and the combination of both drugs in pain management after stent removal. Materials & Methods: Thirty-three patients were divided into three groups. Group I was given diclofenac Sodium 50 mg, group II was given silodosin 8 mg and group III was given the combination of diclofenac sodium 50 mg and silodosin 8 mg. The Wong Baker Pain Scale (WBPS) was assessed serially: two hours before the DJ stent removal, during DJ stent removal, and after the DJ stent removal (2 hours and 24 hours after). The data was analyzed by ANOVA and Kruskal-Wallis test. Results: In this study, 33 patients who underwent DJ stent removal were obtained. Wong Baker was presented in median (min-max) form. The WBPS study in each group did not differ statistically significant. Lowest WBPS during DJ stent removal was found in group III. Group III was better and statistically significant in reducing pain compared to group I and group II (p<0.05). WBPS two hours after removal in each group decreased and group III was better and statistically significant in reducing pain compared to group II, whereas group III compared to group I had an equivalent effectiveness. While the WBPS 24 hours after removal had the same value and did not differ significantly. No side effects or adverse events were found in the use of diclofenac sodium, silodosin, and their combinations. Conclusion: Single oral dose of diclofenac sodium combined with silodosin is effective to reduce pain after DJ stent removal.



Silodosin, diclofenac sodium, pain, DJ stent removal, Wong Baker Pain Scale


Liatsikos E. Long Term Stenting of the Ureter. In: Tanagho E., McAninch JW, editors. Smith’s General Urology. 17th ed. 2008. p. 278–96.

Tailly T, Denstedt J. Fundamentals of Urinary Tract. In: Kavoussi LR, Partin AW, Peters CA, Wein AJ, editors. Campbell Walsh Urology. 11th ed. Philadelphia; 2016. p. 126–32, 153–80.

Dellis A, Joshi HB, Timoney AG, Keeley FX. Relief of stent related symptoms: Review of engineering and pharmacological solutions. J Urol. 2010; 184(4): 1267–72.

Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010; 183(2): 598–602.

Tadros NN, Bland L, Legg E, Olyaei A, Conlin MJ. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebocontrolled trial. BJU Int. 2012; 11:101–105

Gangkak G, Teli RD, Yadav SS, Tomar V, Priyadarshi S, Aggarwal SP. A single oral dose of Silodosin and Diclofenac sodium is effective in reducing pain after ureteric stent removal: a prospective, randomized, double blind placebo ‑ controlled study. Springerplus. 2016; 5: 23.

Monga M, Miyaoka R. Ureteral stent discomfort: Etiology and management. Indian J Urol. 2009; 25(4): 455.

Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007; 14(8): 749–53.

Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011; 77(3): 762.e13-762.e17.

Chaignat V, Danuser H, Stoffel MH, Z’Brun S, Studer UE, Mevissen M. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol. 2008; 154(6): 1297–307.

Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis. 2004; 25(2): 237–40.

Russo A, Hedlund P, Montorsi F. Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy. Vol. 10, European Urology, Supplements. Elsevier; 2011. p. 445–50.

Novara G, Tubaro A, Sanseverino R, Spatafora S, Artibani W, Zattoni F, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013; 31(4): 997–1008.

Choo MS, Song M, Kim JH, Lee KS, Kim JC, Kim SW, et al. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (silver study): A 12-week, double-blind, randomized, parallel, multicenter study. Urology. 2014; 83(4): 875–81.

Tsai P, Wang C, Chang C, Chen H, Hsu C. Effects of Silodosin on Lower Urinary Tract Symptoms Due to a Double-J Stent: A Prospective Randomized Study. Int J Nephrol Kidney Fail (ISSN 2380-5498). 2015; 1(3).

Zhang P, Hu WL, Cheng B, Cheng L, Zeng YJ, Wang G. α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis. Exp Ther Med. 2016; 11(2): 660–8.

Kinnman E, Nyg??rds EB, Hansson P. Peripherally administrated morphine attenuates capsaicin-induced mechanical hypersensitivity in humans. Anesth Analg. 1997; 84(3): 595–9.

Jayant K, Agrawal R, Agrawal S. Tamsulosin versus tamsulosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomized controlled trial. Int J Urol. 2014; 21(10): 1012–5.

Gratzke C, Ückert S, Kedia G, Reich O, Schlenker B, Seitz M, et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: A basic research approach. Urol Res. 2007; 35(1): 49–54.

Kaneko T, Matsushima H, Morimoto H, Tsuzaka Y, Homma Y. Efficacy of low dose tamsulosin in medical expulsive therapy for ureteral stones in Japanese male patients: A randomized controlled studyInvestigation. Int J Urol. 2010; 17(5): 462–5.

Karabacak OR, Yilmazer D, Ozturk U, Sener NC, Saltas H, Karabacak Y, et al. The presence and distribution of alpha adrenergic receptors in human renal pelvis and calyces. Urol Res. 2013; 41(5): 385–8.

Canda AE, Turna B, Cinar GM, Nazli O. Physiology and pharmacology of the human ureter: Basis for current and future treatments. Urol Int. 2007; 78(4): 289–98.

Çervenàkov I, Fillo J, Mardiak J, Kopečnú M, Šmirala J, Lepieš P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker - Tamsulosin. Int Urol Nephrol. 2002; 34(1): 25–9.

Zhang M-Y, Ding S-T, Lu J-J, Lue Y-H, Zhang H, Xia Q-H. Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones. Chin Med J (Engl). 2009; 122(7): 798–801.

Summertom DJ, Djakovic N. Pain Management After Urological Operations. In: European Association of Urology Guidelines. 2017th ed. 2013. p. 30–1.

Tadros NN, Bland L, Legg E, Olyaei A, Conlin MJ. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: A prospective, randomised, double-blind, lacebo-controlled trial. BJU Int. 2013; 111(1): 101–5.

Nakada SY, Jerde TJ, Bjorling DE, Saban R. Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: A better alternative for renal colic? J Urol. 2000; 163(2): 607–12.

Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fernández Fernández E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011; 59(3): 342–52.

Trevor A, Katzung B, Masters S. Katzung & Tevor’s Pharmacology; 2005. p. 307-30.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University